Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00728598|
Recruitment Status : Completed
First Posted : August 6, 2008
Last Update Posted : August 6, 2008
|Condition or disease|
|Proliferative Diabetic Retinopathy Angiogenesis|
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Observational Model:||Case Control|
|Official Title:||Vitreous Levels of Patients With Proliferative Diabetic Retinopathy.|
|Study Start Date :||January 1998|
|Actual Primary Completion Date :||December 1998|
|Actual Study Completion Date :||December 1998|
Proliferative diabetic retinopathy, active.
Proliferative diabetic retinopathy, quiescent.
Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.
- Vitreous levels and serum levels of Fractalkine, VEGF, other growth factor. [ Time Frame: vitreous sample collected on vitrectomy ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00728598
|The department of ophthalmology, National Taiwan University Hospital|
|Principal Investigator:||Chang-Hao Yang, MD, PhD||Ophthalmology, National Taiwan University Hospital|